Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | GALR2 | O43603 | 3/20 | 0.47 |
| ▸ | GALR1 | P47211 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Obefazimod SCHEMBL1705888 | 0.87 | DHFR (0.54) | CTSCCHRNA7DHFR | |
| Obefazimod SCHEMBL29157012 | 0.86 | DHFR (0.53) | CTSCCHRNA7DHFR | |
| Obefazimod SCHEMBL30729382 | 0.86 | DHFR (0.53) | CTSCCHRNA7DHFR | |
| SCHEMBL1702531 | 0.84 | SYK (0.40) | CTSCIGF1RSYKDHFRP2RX3 | |
| SCHEMBL30603856 | 0.83 | MEN1 (0.60) | IGF1R | |
| SCHEMBL29110571 | 0.83 | MEN1 (0.60) | IGF1R | |
| SCHEMBL30764789 | 0.82 | KDR (0.41) | CTSCSYKDHFR | |
| SCHEMBL21621091 | 0.82 | KDR (0.41) | CTSCSYKDHFR | |
| SCHEMBL1705791 | 0.81 | P2RX7 (0.42) | CTSCCHRNA7DHFR | |
| SCHEMBL30764788 | 0.81 | P2RX7 (0.42) | CTSCCHRNA7DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | claimed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | claimed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| CN-102625804-A | Compounds for the treatment of AIDS | SPLICOS SOC | 2012-08-01 | — | — | CN | claimed |
| CN-102596935-A | Compounds for the treatment of premature aging and especially premature aging | SPLICOS SOC | 2012-07-18 | — | — | CN | claimed |
| CN-102574835-A | Compounds for the treatment of cancer | SPLICOS SOC | 2012-07-11 | — | — | CN | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| EP-2440545-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017498-B2 | Compounds useful for treating AIDS | NR1H3, NR1H2, NR1H4 | CTSC 3026/4885IGF1R 2342/4885GALR2 736/4885 |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | CTSC 3436/4885IGF1R 4276/4885GALR2 2498/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | CTSC 4360/4885IGF1R 2609/4885GALR2 2270/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | CTSC 3482/4885IGF1R 1219/4885GALR2 371/4885 |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR1H2, NR1H4 | CTSC 3026/4885IGF1R 2342/4885GALR2 736/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | CTSC 4068/4885IGF1R 3471/4885GALR2 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.